Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Franck Morschhauser
Research Funding - Genentech
Ian Flinn
Research Funding - Genentech
Ranjana H. Advani
Research Funding - Genentech
Laurie Helen Sehn
No relevant relationships to disclose
Kathryn S. Kolibaba
No relevant relationships to disclose
Oliver W. Press
Research Funding - Genentech
Gilles A. Salles
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Catherine S. Magid Diefenbach
Honoraria - Roche
Herve Tilly
Honoraria - Roche
Sarit E. Assouline
No relevant relationships to disclose
Andrew Tzong-Yow Chen
Consultant or Advisory Role - Genentech
Martin H. Dreyling
Honoraria - Genentech
Research Funding - Genentech
Anton Hagenbeek
No relevant relationships to disclose
Pier Luigi Zinzani
Consultant or Advisory Role - Genentech
Bruce D. Cheson
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Sreenivasu Yalamanchili
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Dan Lu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Akiko Chai
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Yu-Waye Chu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jeff Porter Sharman
Research Funding - Genentech